Moderate ResearchLongevityMetabolic

Pancragen

KEDW

KEDW Tetrapeptide | Pancreas Bioregulator

Half-life

Not established

Chain length

4 amino acids

Reference frequency

Daily for 10-20 days per cycle

Research overview

DoseGear research brief

Pancragen is a Khavinson bioregulator tetrapeptide (KEDW) originally isolated from bovine pancreatic cells. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it directly interacts with DNA to regulate pancreatic gene expression. Research in old rhesus monkeys demonstrated that Pancragen corrected impaired glucose tolerance, normalized insulin and C-peptide levels, and improved endocrine pancreatic function. It is considered safe and effective for age-related metabolic disturbances.

Mechanism of action

Pancragen works through epigenetic regulation by interacting with chromatin complexes and DNA structures to modulate pancreatic gene expression. Research shows it upregulates critical transcription factors for pancreatic cell maturation including Pdx1, Pax6, Ptf1a, Foxa2, Nkx2. 2, and Pax4. Its small size (4 amino acids, ~576 Da) allows it to traverse cellular membranes and interact with nuclear components including histones and DNA.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Khavinson-associated pancreatic bioregulator peptide.

What it is researched for

Experimental pancreatic and glucose-regulation research through proposed tissue-specific gene-regulatory effects.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

No sourced lyophilized-vial injectable protocol is listed for this profile.

Safety context

Reported side effects

Generally well-tolerated
Minimal side effects reported

Contraindications & cautions

Active pancreatic emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Type 1 diabetes (consult physician)

Scientific references

01
Correction of Impaired Glucose Tolerance Using Tetrapeptide (Pancragen) in Old Female Rhesus Monkeys
Scientific citationCorrection of Impaired Glucose Tolerance Using Tetrapeptide (Pancragen) in Old Female Rhesus Monkeys. PubMed (2017).
02
Tetrapeptide KEDW Interacts with DNA and Regulates Gene Expression
Scientific citationTetrapeptide KEDW Interacts with DNA and Regulates Gene Expression. Bulletin of Experimental Biology and Medicine (2015).
03
Impacts of Pancragen on Differentiation of Pancreatic Cells During Aging
Scientific citationImpacts of Pancragen on Differentiation of Pancreatic Cells During Aging. Bulletin of Experimental Biology and Medicine (2013).
04
Prospects of Using Pancragen for Metabolic Disorders in Elderly
Scientific citationProspects of Using Pancragen for Metabolic Disorders in Elderly. Bulletin of Experimental Biology and Medicine (2011).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity